ACM
TARS icon

Atika Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Atika Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Buy
+40,000
New +$2.56M 0.17% 72
2025
Q2 		– Sell
-144,400
Closed -$7.42M – 77
2025
Q1 		$7.42M Sell
144,400
-32,800
-19% -$1.62M 1.04% 30
2024
Q4 		$9.81M Buy
+177,200
New +$8.05M 1.04% 31

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Atika Capital Management's TARS Position: Q2 2026 in Review

Atika Capital Management opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 40,000 shares worth $2.52M. The stake represents 0.17% of the portfolio and ranks #72 among its holdings. This is a return to the name: Atika Capital Management previously reported a position in TARS as recently as Q1 2025.

Atika Capital Management first reported a position in TARS in Q4 2024 and has held it in 3 quarters since. The position peaked at $9.81M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Atika Capital Management held 40,000 shares of Tarsus Pharmaceuticals worth $2.52M as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Atika Capital Management position in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.17% of Atika Capital Management's portfolio in Q2 2026, its #72 holding.
  • Atika Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Atika Capital Management's Tarsus Pharmaceuticals position peaked at $9.81M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.